Literature DB >> 16920101

Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures.

Stephen H Reaney1, Louisa C Johnston, William J Langston, Donato A Di Monte.   

Abstract

Impairment of the ubiquitin-proteasome system (UPS) has been implicated in the pathogenesis of Parkinson's disease (PD). Because the neurodegenerative process of PD results in a severe loss of dopaminergic cells, previous in vitro studies have investigated the possibility that these neurons may be particularly vulnerable to proteasomal inhibition. Results of this earlier work are difficult to compare, however, since they were obtained using different proteasomal inhibitors at various concentrations and under diverse culture conditions. Here, four UPS inhibitors, i.e., lactacystin, PSI, epoxomicin and MG-132, were directly evaluated in terms of their ability to damage dopaminergic and GABAergic neurons in primary rat mesencephalic cultures. Using a broad range of concentrations and different incubation lengths, we found that proteasomal inhibitors consistently killed both dopaminergic and GABAergic neurons. The degree of toxicity was slightly different, however, between the two neuronal populations. When measurements of neurotransmitter uptake were used as indicators of neuronal cell viability, the extent of reduction of dopamine uptake caused by proteasomal inhibitors was slightly greater than the decrease in GABA uptake. With PSI the difference in reduction of dopamine vs. GABA uptake was less than 10% and did not reach statistical significance. With the other three inhibitors, dopaminergic cells were up to 20% more affected than GABAergic neurons; this difference reached statistical significance only at specific concentrations and time points. Preincubation of cultures with alpha-methyl-p-tyrosine, an inhibitor of dopamine synthesis, reduced dopamine concentration by 65% but failed to significantly change lactacystin- and MG-132-induced damage to dopaminergic neurons. Data indicate a modest preferential toxicity of proteasomal inhibitors toward dopaminergic cells and thus only in part support the hypothesis that a selective vulnerability to UPS dysfunction underlies the pathogenesis of nigrostriatal degeneration in PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920101     DOI: 10.1016/j.expneurol.2006.07.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  10 in total

1.  A role for the ubiquitin-proteasome system in activity-dependent presynaptic silencing.

Authors:  Xiaoping Jiang; Patricia E Litkowski; Amanda A Taylor; Ying Lin; B Joy Snider; Krista L Moulder
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

2.  The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions.

Authors:  D Jantas; A Roman; J Kuśmierczyk; E Lorenc-Koci; J Konieczny; T Lenda; W Lasoń
Journal:  Neurotox Res       Date:  2013-01-10       Impact factor: 3.911

3.  Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease.

Authors:  Anthony C Vernon; William R Crum; Saga M Johansson; Michel Modo
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

4.  Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis.

Authors:  Sung-Man Jeon; Sang-Myung Cheon; Hye-Rahn Bae; Jae Woo Kim; Seung U Kim
Journal:  Exp Neurobiol       Date:  2010-12-31       Impact factor: 3.261

5.  Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.

Authors:  Jolanta Konieczny; Danuta Jantas; Tomasz Lenda; Helena Domin; Anna Czarnecka; Katarzyna Kuter; Maria Śmiałowska; Władysław Lasoń; Elżbieta Lorenc-Koci
Journal:  Neurotox Res       Date:  2014-05-20       Impact factor: 3.911

6.  Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein.

Authors:  Eduard Bentea; Anke Van der Perren; Joeri Van Liefferinge; Anissa El Arfani; Giulia Albertini; Thomas Demuyser; Ellen Merckx; Yvette Michotte; Ilse Smolders; Veerle Baekelandt; Ann Massie
Journal:  Front Behav Neurosci       Date:  2015-03-31       Impact factor: 3.558

7.  Development of Small Molecular Proteasome Inhibitors Using a Caenorhabditis elegans Screen.

Authors:  Sudhir Nayak; Michela Fiaschi; Dana King; Erica R Tabakin; Lyndsay Wood; David A Hunt
Journal:  Int J Med Chem       Date:  2014-11-11

Review 8.  The Proteasome Inhibition Model of Parkinson's Disease.

Authors:  Eduard Bentea; Lise Verbruggen; Ann Massie
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

9.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

10.  Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation.

Authors:  Faneng Sun; Arthi Kanthasamy; Chunjuan Song; Yongjie Yang; Vellareddy Anantharam; Anumantha G Kanthasamy
Journal:  J Cell Mol Med       Date:  2008-02-24       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.